Healthcare entity

Oramed Pharmaceuticals

Company ORMP

Every one of those 1 sits in a single category, acquisition. Of the tracked stories, 1 of 1 also mention Lifeward Ltd, the most common co-covered peer. Each story carries 2 original sources on average, compared with 5.1 for the broader beat in this window.

Last mentioned: Mar 13, 2026

Entity pulse

Recent coverage · Oramed Pharmaceuticals

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Oramed Pharmaceuticals

Every one of those 1 sits in a single category, acquisition. Of the tracked stories, 1 of 1 also mention Lifeward Ltd, the most common co-covered peer. Each story carries 2 original sources on average, compared with 5.1 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.1. Oramed Pharmaceuticals appears in 1 tracked Healthcare story from March 13, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Oramed Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Financial Reporting

    Lifeward scheduled to report Q4 and full-year 2025 financial results.

  2. Shareholder Approval

    Lifeward shareholders vote in favor of the strategic partnership with Oramed.

  3. Nasdaq Compliance

    Lifeward regains compliance with Nasdaq minimum bid price requirements.

Stories mentioning Oramed Pharmaceuticals 1

Acquisitions Positive

Lifeward and Oramed Secure Shareholder Approval for Strategic Biomedical Merger

Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.

2 sources

Source: finanznachrichten.de · manilatimes.net

Oramed Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.